Shots:

• The P-III HLX04-mCRC03 study involve assessing of HLX04 (7.5mg/kg- q3w- when combined with XELOX or 5mg/kg- q2w when combined with mFOLFOX6) vs reference bevacizumab + CT (XELOX or mFOLFOX6) as a 1L treatment in 675 patients in a ratio (1:1) with mCRC
• Results: PFSR36wk  (46.4% vs 50.7%); no difference in 2EPs including OS- PFS- ORR- TTR and DoR
• HLX04 is a bevacizumab biosimilar- indicated for advanced- metastatic- or recurrent NSCLC and metastatic colorectal cancer. Additionally- NMPA has accepted NDA of HLX04

­ Ref: Henlius | Image: Henlius